Regeneron and Fujifilm Diosynth Biotechnologies Announce Groundbreaking $3 Billion Deal

In a significant move to bolster the production of commercial biologic medicines in the United States, Regeneron Pharmaceuticals Inc. has entered into a monumental agreement with Fujifilm Diosynth Biotechnologies. This collaboration, centered at Fujifilm's campus in North Carolina, is set to exceed $3 billion in total investment, encompassing technology transfer and a decade-long commitment.

Daniel Van Plew, Executive Vice President of Regeneron, expressed enthusiasm about the partnership, stating, "Our collaboration with Fujifilm is a testament to our shared commitment to excellence and innovation. We are confident in their ability to meet our stringent standards and are eager to ramp up production at their Holly Springs facility."

Additionally, Regeneron highlighted its broader investment strategy, with over $7 billion earmarked for expanding production and infrastructure across New York and North Carolina, signaling a robust growth trajectory in the biopharmaceutical sector.